Biodexa Pharmaceuticals PLC

About Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing a pipeline of treatments for diseases with high unmet clinical needs. Their mission is to advance medicines for a brighter future, with a lead program targeting familial adenomatous polyposis (FAP) and other initiatives addressing type 1 diabetes and brain cancers.

Products & Services

eRapa:A proprietary oral tablet formulation of rapamycin (sirolimus), an mTOR inhibitor, designed to improve bioavailability and achieve consistent pharmacokinetics using nanotechnology and pH-sensitive polymers. It is being prepared for a Phase 3 study for familial adenomatous polyposis (FAP).

Tolimidone:An orally delivered, potent, and selective inhibitor of lyn kinase, demonstrating glycemic control via insulin sensitization in animal models of diabetes, with potential as a first-in-class blood glucose modulating agent.

Specialties

Development of treatments for diseases with unmet clinical needs Familial Adenomatous Polyposis (FAP) therapies Type 1 Diabetes treatments Brain cancer therapies (primary and metastatic) Nanotechnology and pH-sensitive polymer formulations mTOR inhibitors Lyn kinase inhibitors

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 10000000 MR: - FA: $10 Million FAN: 10000000	D: 2025-12-18 FD: 2025-12-18	-
2	RT: Grant T: - FT: Grant	A: 3000000 MR: - FA: Additional $3.0M Grant FAN: 3000000	D: 2025-05-22 FD: 2025-05-22	1 investors
3	RT: Grant T: - FT: Grant	A: 3000000 MR: - FA: $3.0MM FAN: 3000000	D: 2024-09-16 FD: 2024-09-16	1 investors
4	RT: Registered Direct Offering and Private Placement T: - FT: Registered Direct Offering and Private Placement	A: 5000000 MR: - FA: 5.0 Million FAN: 5000000	D: 2024-07-23 FD: 2024-07-23	-
5	RT: Registered Direct Offering and Private Placement T: - FT: Registered Direct Offering and Private Placement	A: 5000000 MR: - FA: 5.0 Million FAN: 5000000	D: 2024-07-19 FD: 2024-07-19	1 investors
6	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 7000000 MR: - FA: $7 million FAN: 7000000	D: 2024-05-22 FD: 2024-05-22	1 investors
7	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 6000000 MR: - FA: 6.0 Million FAN: 6000000	D: 2023-12-21 FD: 2023-12-21	1 investors
8	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 5200000 MR: - FA: $5.2 Million FAN: 5200000	D: 2023-12-19 FD: 2023-12-19	1 investors
9	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 3320000 MR: - FA: $3.32 Million FAN: 3320000	D: 2023-05-26 FD: 2023-05-26	-
10	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 3320000 MR: - FA: US$3.32 Million FAN: 3320000	D: 2023-05-24 FD: 2023-05-24	-
11	RT: Equity T: - FT: Equity	A: 502 MR: - FA: US$502.04 FAN: 502	D: 2023-04-20 FD: 2023-04-20	-
12	RT: Equity T: - FT: Equity	A: 300 MR: - FA: US$300.00 FAN: 300	D: 2023-04-05 FD: 2023-04-05	-
13	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 773 MR: - FA: US$773.24 FAN: 773	D: 2023-04-04 FD: 2023-04-04	-
14	RT: Private Placement T: - FT: Private Placement	A: 12444558 MR: - FA: 12,444,558 FAN: 12444558	D: 2023-04-03 FD: 2023-04-03	-

Public Offering Latest

2025-12-18

$10.0M

Grant 2025-05-22

$3.0M

Grant 2024-09-16

$3.0M

View 13 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Stephen Stamp

CEO / CFO

G

Gary Shangold

Chief Medical Officer

D

Dan Palmer

VP Technology

F

Fiona Sharp

Group Financial Controller

S

Steve Ellul

Chief Business Officer

N

Noreen Bhatti

Vice President of Clinical Operations

View 7 more team members with Pro

Unlock Full Team Directory

Recent News